UPCC 57418: A Phase III Multicenter Randomized Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes

Enrolling By Invitation
99 years or below
All
Phase 3

Brief description of study

This is a study of the effectiveness and safety of giving the experimental drug, APR-246, together with the drug azacitidine to patients with MDS that has not yet been treated with chemotherapy or hypomethylating agents like azacitidine, compared with just giving azacitidine alone.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Myelodysplastic Syndromes
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832565
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

 

Interested in the study?

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact a study center.